Shares of Radian Group Inc.(NYSE:RDN) jumped another 8% to $4.37 in the opening session after soaring 22.50% in the previous trading session.
Yesterday, shares in Radian Group soared after the company released delinquency data for August which showed a drop during the month.
The mortgage insurer started the month with 97,012 primary delinquent loans and ended it with 94,823 delinquent loans, the company said on Thursday.
It also said that it had got back $120 million in after-tax securities in its investment portfolio and was able to place more risk to a re-insurer than had been previously agreed to in a deal.
Will RDN Continue To Move Higher? Find Out Here
Radian shares rose 74 cents to close at $4.04
In another development Internet retailer Amazon.com, Inc.(NASDAQ:AMZN) unveiled a slew of Kindle Fire tablets on Thursday, upping the ante in its fight with Apple, Google and Netflix.
The company is banking on its huge content, including videos and music, at its disposal to make its tablet PCs more popular and attractive for customers.
Amazon shares jumped 2 percent in normal trading at $256.32 and made an all time high of $256.58.
Should Investors Buy AMZN After Recent Rally? Find Out Here
“Last year, there were more than two dozen Android tablets launched and nobody bought them,” said Amazon Chief Executive Jeff Bezos at the event, referring to Google’s mobile device operating software.
The new Kindle Fire HD device will come in two screen sizes and features a front facing camera, for $199 to $299, said Bezos.
Also an updated version of Amazon’s original Kindle Fire tablet will ship on Sept. 14 for $159, he said.
Orexigen Therapeutics, Inc.(NASDAQ:OREX) rose another 2% to $5.85 after soaring 25% in the past two sessions.
Yesterday credit Suisse initiated coverage of Orexigen sock on Thursday with an outperform rating sending its share price up 19 percent in intra-day trades.
Is It The Right Time To Buy OREX? Get Free Trend Analysis Here
The shares finally closed up 16.7 percent at $5.73. The shares have appreciated by a third in the past 30 days and more than trebled so far in 2012. The market has been reacting to speculation that the U.S. drug regulator may approve its diet drug Contrave.